DK1506295T3 - Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf - Google Patents

Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf

Info

Publication number: DK1506295T3
Authority: DK; Denmark
Prior art keywords: preparation; growth factor; muteins; placental growth; applications
Prior art date: 2002-05-17

Application number

DK03727958.5T

Other languages

English (en)

Inventor

Mauro Battisti

Ettore Conti

Giuseppe Salvia

Marina Tucci

Alberto Mion

Domenico Maglione

Original Assignee

Geymonat Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2003-05-19

Publication date

2011-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11456311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1506295(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-19 Application filed by Geymonat Spa filed Critical Geymonat Spa

2011-03-07 Application granted granted Critical

2011-03-07 Publication of DK1506295T3 publication Critical patent/DK1506295T3/da

Links

101000595923 Homo sapiens Placenta growth factor Proteins 0.000 title abstract 3
102100035194 Placenta growth factor Human genes 0.000 title abstract 3
238000002360 preparation method Methods 0.000 title abstract 2
239000002537 cosmetic Substances 0.000 abstract 2
230000001173 tumoral effect Effects 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000008030 elimination Effects 0.000 abstract 1
238000003379 elimination reaction Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Toxicology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK03727958.5T 2002-05-17 2003-05-19 Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf DK1506295T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2002RM000277A ITRM20020277A1 (it)	2002-05-17	2002-05-17	Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
PCT/IT2003/000296 WO2003097688A2 (en)	2002-05-17	2003-05-19	Muteins of placental growth factor type 1, preparation method and application thereof

Publications (1)

Publication Number	Publication Date
DK1506295T3 true DK1506295T3 (da)	2011-03-07

Family

ID=11456311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03727958.5T DK1506295T3 (da)	2002-05-17	2003-05-19	Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf

Country Status (21)

Country	Link
US (1)	US7314734B2 (da)
EP (1)	EP1506295B1 (da)
JP (1)	JP4230450B2 (da)
KR (1)	KR101022934B1 (da)
CN (1)	CN1323167C (da)
AT (1)	ATE488590T1 (da)
AU (1)	AU2003234066B2 (da)
BR (1)	BR0309966A (da)
CA (1)	CA2485587C (da)
CY (1)	CY1111431T1 (da)
DE (1)	DE60334986D1 (da)
DK (1)	DK1506295T3 (da)
ES (1)	ES2356360T3 (da)
HR (1)	HRP20041178B1 (da)
IT (1)	ITRM20020277A1 (da)
MX (1)	MXPA04011405A (da)
PL (1)	PL209955B1 (da)
PT (1)	PT1506295E (da)
RU (1)	RU2344172C2 (da)
WO (1)	WO2003097688A2 (da)
ZA (1)	ZA200409943B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2509063C (en)	2002-11-16	2010-11-02	Dade Behring Marburg Gmbh	Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
DE102005022047A1 (de)	2005-05-09	2006-11-30	Dade Behring Marburg Gmbh	Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
JP2009100680A (ja) *	2007-10-23	2009-05-14	Univ Nagoya	ヒト全身性強皮症動物モデルの作製方法、ヒト全身性強皮症動物モデル及びその用途
RU2010133157A (ru)	2008-01-07	2012-02-20	Орто-Клиникал Дайэгностикс, Инк. (Us)	Определение комплекса sflt-1:ангиогенный фактор
CN101918834B (zh) *	2008-01-07	2014-05-28	奥索临床诊断有限公司	用于同时分析能够彼此络合的蛋白质的校准物/对照物
EP2295449A1 (en)	2009-09-09	2011-03-16	Dompe PHA.R.MA S.p.A.	PLGF-1 in homodimeric form
CN103087153B (zh) *	2011-10-28	2015-05-06	上海市第一人民医院	一类新的抑制新生血管的小肽及其应用
EP3511014A1 (en)	2013-05-31	2019-07-17	CoBioRes NV	Human plgf-2 for the prevention or treatment of heart failure resulting from chronic myocardial ischemia
CN109134650A (zh) *	2018-09-10	2019-01-04	宁波奥丞生物科技有限公司	抗人plgf单克隆抗体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2107727C1 (ru) *	1988-03-23	1998-03-27	Яманути Фармасьютикал Ко., Лтд.	Рекомбинантный тканевой активатор плазминогена и способ его получения
IT1242149B (it) *	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
DE69229454T2 (de) *	1991-03-28	2000-01-05	Merck & Co., Inc.	Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
SE9601245D0 (sv) *	1996-03-29	1996-03-29	Pharmacia Ab	Chimeric superantigens and their use
DE19748734A1 (de) *	1997-11-05	1999-05-06	Biotechnolog Forschung Gmbh	Verfahren zur Gewinnung von biologisch aktiven Dimeren von rekombinanten humanen Wachstumsfaktoren aus der Cystein-Knoten-Familie sowie Verwendung der gewonnenen Dimere
AU5306700A (en) *	1999-06-03	2000-12-28	Human Genome Sciences, Inc.	Angiogenic proteins and uses thereof
DK1297016T3 (da) *	2000-05-12	2006-07-10	Vlaams Interuniv Inst Biotech	Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage

2002
- 2002-05-17 IT IT2002RM000277A patent/ITRM20020277A1/it unknown
2003
- 2003-05-19 CN CNB038112043A patent/CN1323167C/zh not_active Expired - Fee Related
- 2003-05-19 PL PL372492A patent/PL209955B1/pl unknown
- 2003-05-19 WO PCT/IT2003/000296 patent/WO2003097688A2/en not_active Ceased
- 2003-05-19 PT PT03727958T patent/PT1506295E/pt unknown
- 2003-05-19 AT AT03727958T patent/ATE488590T1/de active
- 2003-05-19 DE DE60334986T patent/DE60334986D1/de not_active Expired - Lifetime
- 2003-05-19 RU RU2004137000/13A patent/RU2344172C2/ru not_active IP Right Cessation
- 2003-05-19 HR HRP20041178AA patent/HRP20041178B1/hr not_active IP Right Cessation
- 2003-05-19 US US10/514,707 patent/US7314734B2/en not_active Expired - Fee Related
- 2003-05-19 MX MXPA04011405A patent/MXPA04011405A/es active IP Right Grant
- 2003-05-19 CA CA2485587A patent/CA2485587C/en not_active Expired - Fee Related
- 2003-05-19 JP JP2004506360A patent/JP4230450B2/ja not_active Expired - Fee Related
- 2003-05-19 ES ES03727958T patent/ES2356360T3/es not_active Expired - Lifetime
- 2003-05-19 DK DK03727958.5T patent/DK1506295T3/da active
- 2003-05-19 AU AU2003234066A patent/AU2003234066B2/en not_active Ceased
- 2003-05-19 EP EP03727958A patent/EP1506295B1/en not_active Expired - Lifetime
- 2003-05-19 BR BR0309966-0A patent/BR0309966A/pt not_active IP Right Cessation
- 2003-05-19 KR KR1020047018601A patent/KR101022934B1/ko not_active Expired - Fee Related
2004
- 2004-12-08 ZA ZA2004/09943A patent/ZA200409943B/en unknown
2011
- 2011-02-16 CY CY20111100200T patent/CY1111431T1/el unknown

Also Published As

Publication number	Publication date
DE60334986D1 (de)	2010-12-30
AU2003234066A1 (en)	2003-12-02
PT1506295E (pt)	2011-02-23
JP2006508637A (ja)	2006-03-16
RU2344172C2 (ru)	2009-01-20
EP1506295A2 (en)	2005-02-16
AU2003234066B2 (en)	2009-04-23
CN1323167C (zh)	2007-06-27
KR101022934B1 (ko)	2011-03-16
US7314734B2 (en)	2008-01-01
ITRM20020277A1 (it)	2003-11-17
CA2485587C (en)	2012-08-21
BR0309966A (pt)	2005-03-01
MXPA04011405A (es)	2005-02-14
WO2003097688A2 (en)	2003-11-27
CY1111431T1 (el)	2015-08-05
HRP20041178A2 (en)	2005-10-31
PL372492A1 (en)	2005-07-25
HRP20041178B1 (hr)	2013-11-22
KR20040111639A (ko)	2004-12-31
ATE488590T1 (de)	2010-12-15
WO2003097688A9 (en)	2005-01-06
RU2004137000A (ru)	2005-06-10
PL209955B1 (pl)	2011-11-30
ES2356360T3 (es)	2011-04-07
JP4230450B2 (ja)	2009-02-25
ITRM20020277A0 (it)	2002-05-17
CA2485587A1 (en)	2003-11-27
HK1079549A1 (en)	2006-04-07
CN1653177A (zh)	2005-08-10
EP1506295B1 (en)	2010-11-17
ZA200409943B (en)	2005-09-28
WO2003097688A3 (en)	2004-02-26
US20050176634A1 (en)	2005-08-11

Publication	Publication Date	Title
RU2009100884A (ru)	2010-07-20	Пептидные фрагменты для индукции синтеза белков внеклеточного матрикса
CY1111431T1 (el)	2015-08-05	Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
ATE446313T1 (de)	2009-11-15	Muteine von tränen-lipocalin
DE50004018D1 (de)	2003-11-13	Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
ATE417595T1 (de)	2009-01-15	Keratin-bindende polypeptide
TR200401029T4 (tr)	2004-06-21	Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
FI860153A0 (fi)	1986-01-13	Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning.
NO20071369L (no)	2007-05-04	Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv
ATE169304T1 (de)	1998-08-15	Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
HUP0004560A2 (hu)	2001-04-28	Törést gyógyító PTHrP analógok
PL2157192T3 (pl)	2014-01-31	Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
BRPI0314666B8 (pt)	2022-11-22	composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune
DE69900756D1 (de)	2002-02-28	Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE602006020898D1 (de)	2011-05-05	Peptide zur förderung des haarwachstums und zur verbesserung von falten und kosmetische zusammensetzungen, die diese enthalten
KR950032165A (ko)	1995-12-20	토코페롤 유도체
NO20010940D0 (no)	2001-02-23	TAN-1057 derivater
DE60322064D1 (de)	2008-08-21	4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
HRP20050787A2 (en)	2006-12-31	Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
KR940007059A (ko)	1994-04-26	변형된 혈소판 인자-4
DE69834929D1 (de)	2006-07-27	Verwendung eines organspezifischen ernährungmittels
ATE425174T1 (de)	2009-03-15	Colchicosidanaloge
CY1105105T1 (el)	2009-11-04	Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
ATE291587T1 (de)	2005-04-15	Somatostatin analoge und deren verwendung zur behandlung von krebs
DK0423326T3 (da)	1999-05-25	Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
ATE402178T1 (de)	2008-08-15	Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten